1993
Nitric Oxide Modulates Lymphocyte Proliferation But Not Secretion of IL-2
Huot AE, Moore AL, Roberts JD, Hacker MP. Nitric Oxide Modulates Lymphocyte Proliferation But Not Secretion of IL-2. Immunological Investigations 1993, 22: 319-327. PMID: 7689536, DOI: 10.3109/08820139309063411.Peer-Reviewed Original ResearchConceptsLymphocyte proliferationBAL cellsIL-2Nitric oxideNO synthase inhibitor NG-monomethylSynthase inhibitor NG-monomethylExcess IL-2Bronchoalveolar lavage cellsInhibitor NG-monomethylCytokines IL-2Time of sacrificeIL-2 productionInterleukin-2 productionModulate lymphocyte proliferationSource of NOIL-2-dependent CTLL-2 cellsLavage cellsNG-monomethylCytokine releaseIntratracheal doseCTLL-2 cellsL-arginineLymphocyte growthMarked inhibitionNO inhibits
1990
Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Research 1990, 50: 6302-10. PMID: 2205379.Peer-Reviewed Original ResearchConceptsLymphokine-activated killer cellsRecombinant interleukin-2LAK activityIL-2Killer cellsDose levelsMononuclear cellsUnits/m2 body surface areaIntraperitoneal recombinant interleukin-2M2 body surface areaLAK/ILOvarian cancer refractorySerum IL-2Less IL-2Dose-limiting toxicityPhase I trialIL-2 levelsAdditional IL-2IL-2-dependent cell lineBody surface areaSignificant weight gainMononuclear cell collectionPeripheral blood cellsHighest dose levelCancer refractory